Inovio Pharmaceuticals Inc (NYSE:INO) CEO Jong Joseph Kim bought 25,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $56,250.00. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -2.62% in last session and finished the day at $2.60. Traded volume was 16.17million shares in the last session and the average volume of the stock remained 7.80million shares. The beta of the stock remained 3.71. Inovio Pharmaceuticals Inc (NYSEMKT:INO) insider ownership is 2.80%.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Bruce Kovner bought 1,250,000 shares of the company’s stock in a transaction that occurred on Friday, April 11th. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) closed to $4.09 Tuesday on volume of 2.60million shares. The intra-day range of the stock was $3.93 to $4.24. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has a market capitalization of $349.43million.

Repligen Corporation (NASDAQ:RGEN) had its buy rating reiterated by analysts at Jefferies Group. Jefferies Group currently has a $17.00 price target on the stock. Repligen Corporation (NASDAQ:RGEN)’s stock on Apr 15, 2014 reported a increase of 5.12% to the closing price of $14.37. Its fifty two weeks range is $7.37 -$17.26. The total market capitalization recorded $460.41million. The overall volume in the last trading session was 858,577.00million shares. In its share capital, RGEN has 32.04million outstanding shares.

On Tuesday, shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) dropped -8.88% to close the day at $40.00. Company return on investment (ROI) is -30.00% and its monthly performance is recorded as -4.24%. Agios Pharmaceuticals Inc (NASDAQ:AGIO) quarterly revenue growth is 12.42%.